US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered …

USWM CT, LLC (US WorldMeds) announced that the U.S. Food and Drug Administration (FDA) has granted full approval of TECELRA® ...
Yahoo Finance

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - ...
Cancer Therapy Advisor

Tecelra Gains Full FDA Approval, Expands to Pediatric Synovial Sarcoma

Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.
FiercePharma

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor

Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma. Tecelra’s approval comes with several firsts. It’s the first ...
WebMD

Tecelra: FDA Expands T-Cell Therapy to Include Patients as Young as 12 Years Old With Advanced Synovial Sarcoma

What Is It, and Why Does It Matter? Tecelra (afamitresgene autoleucel) is a prescription-based personalized T-cell immune therapy for treating synovial sarcoma, a rare type of cancer affecting soft ...
MM&M

Adaptimmune’s Tecelra gains accelerated FDA approval for synovial sarcoma

The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...
Hosted on MSN

Adaptimmune targets $35M–$45M TECELRA sales in 2025 as ATC network nears completion

Management projected "revenue guidance for the full year of between $35 million and $45 million in TECELRA sales." Rawcliffe described the sales range as "roughly, approximately between 50 and 70 ...
Medscape

Treating With Tecelra Post-Approval: What Have Docs Learned?

It’s been just over a year since the FDA approved the first engineered cell therapy for the treatment of certain patients with advanced synovial sarcoma, a rare cancer that affects fewer than 1000 ...
Pharm Exec

FDA Grants Accelerated Approval to Adaptimmune Therapeutics’ Tecelra for Adults with Synovial Sarcoma Who Have Undergone Prior Chemotherapy

Regulatory action marks the first engineered cell therapy approved for a solid tumor cancer in the United States. The FDA has granted accelerated approval to Adaptimmune Therapeutics’ Tecelra ...
Nasdaq

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Several Authorized Treatment Centers (ATCs) are accepting referrals across ...